“…Regarding sepsis, our group and others have described that during experimental and clinical sepsis, NETs are found in high concentrations in the blood and are positively correlated with biomarkers of vital organ injuries and sepsis severity. Furthermore, disruption or inhibition of NET release by pharmacological treatment with recombinant human DNase (rhDNase) or PAD-4 inhibitors, respectively, markedly reduced organ damage, especially in the lungs, and increased the survival rate of severe septic mice ( Colón et al, 2019 ; Czaikoski et al, 2016 ; Kambas et al, 2012 ; Martinod et al, 2015 ; Altrichter et al, 2010 ; Clark et al, 2007 ). The well-known similarities between sepsis and key events involved in the COVID-19 pathophysiology, such as cytokine overproduction ( Mehta et al, 2020 ), microthrombosis ( Magro et al, 2020 ; Dolhnikoff et al, 2020 ), and acute respiratory distress syndrome ( Lai et al, 2020 ), led us to hypothesize that NETs are triggered during SARS-CoV-2 infection and might contribute to tissue injury in COVID-19 patients.…”